Effect of Darapladib onMajor Coronary Events After an Acute Coronary Syndrome The SOLID-TIMI 52 Randomized Clinical Trial

Michelle L. O’Donoghue, MD, MPH; Eugene Braunwald, MD; Harvey D. White, MBChB, DSc; Dylan L. Steen, MD; Mary Ann Lukas, MD; Elizabeth Tarka, MD; P. Gabriel Steg, MD; Judith S. Hochman, MD; Christoph Bode, MD; Aldo P. Maggioni, MD; KyungAh Im, PhD; Jennifer B. Shannon, MS; Richard Y. Davies, MS; Sabina A. Murphy, MPH; Sharon E. Crugnale, MS; Stephen D. Wiviott, MD; Marc P. Bonaca, MD, MPH; David F. Watson, MSc; W. Douglas Weaver, MD; Patrick W. Serruys, MD, PhD; Christopher P. Cannon, MD; for the SOLID-TIMI 52 Investigators

[1]  P. Pais,et al.  Darapladib for preventing ischemic events in stable coronary heart disease. , 2014, The New England journal of medicine.

[2]  A. Postle,et al.  Effect of Darapladib Treatment on Endarterectomy Carotid Plaque Lipoprotein-Associated Phospholipase A2 Activity: A Randomized, Controlled Trial , 2014, PloS one.

[3]  E. Braunwald,et al.  Study design and rationale for the Stabilization of pLaques usIng Darapladib-Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome. , 2011, American heart journal.

[4]  L. Cardon,et al.  Carriage of the V279F Null Allele within the Gene Encoding Lp-PLA2 Is Protective from Coronary Artery Disease in South Korean Males , 2011, PloS one.

[5]  ZiadMallat,et al.  Lipoprotein-Associated and Secreted Phospholipases A2 in Cardiovascular Disease , 2010 .

[6]  I. Verde,et al.  [Lipoprotein-associated phospholipase A(2) and stroke]. , 2009, Revista de neurologia.

[7]  Ping Zhang,et al.  Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development , 2008, Nature Medicine.

[8]  Frits Mastik,et al.  Effects of the Direct Lipoprotein-Associated Phospholipase A2 Inhibitor Darapladib on Human Coronary Atherosclerotic Plaque , 2008, Circulation.

[9]  M. Hanefeld,et al.  The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. , 2008, Journal of the American College of Cardiology.

[10]  J. Alpert,et al.  Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction , 2008 .

[11]  S. Solomon,et al.  Prognostic Utility of Lipoprotein-Associated Phospholipase A2 for Cardiovascular Outcomes in Patients With Stable Coronary Artery Disease , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[12]  A. Siegbahn,et al.  Lipoprotein-associated phospholipase A2 does not predict mortality or new ischaemic events in acute coronary syndrome patients. , 2007, European heart journal.

[13]  A. Moss,et al.  High lipoprotein-associated phospholipase A2 is a risk factor for recurrent coronary events in postinfarction patients. , 2006, Clinical chemistry.

[14]  H. Brenner,et al.  Lipoprotein-Associated Phospholipase A2 Predicts Future Cardiovascular Events in Patients With Coronary Heart Disease Independently of Traditional Risk Factors, Markers of Inflammation, Renal Function, and Hemodynamic Stress , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[15]  M. Sabatine,et al.  Lipoprotein-Associated Phospholipase A2 and Its Association With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy–Thrombolysis In Myocardial Infarction) Trial , 2006, Circulation.

[16]  U. Ikeda,et al.  Lysophosphatidylcholine induces apoptosis in human endothelial cells through a p38-mitogen-activated protein kinase-dependent mechanism. , 2002, Atherosclerosis.

[17]  M. Yen,et al.  Lysophosphatidylcholine induces apoptotic and non-apoptotic death in vascular smooth muscle cells: in comparison with oxidized LDL. , 2000, Atherosclerosis.

[18]  T. Häkkinen,et al.  Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[19]  D. Tew,et al.  Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. , 1999, The Biochemical journal.